Progression of diabetic nephropathy a focus on arterial pressure level and methods of reduction

Diabetes Research and Clinical Practice

Volumn 39, Issue SUPPL., 1998, Pages

  Bakris, George L ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ACE inhibitors; Calcium antagonists; Diabetes; Nephropathy; Proteinuria

Indexed keywords

AMLODIPINE; BENAZEPRIL; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; HUMAN; NONHUMAN; PROTEINURIA;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION;

EID: 0031750616     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(98)00019-9     Document Type: Article

References (59)

1. Barnett A.H. Diabetes and hypertension. Br. Med. Bull. 50(2):1994;397-407.
2. R.G. Nelson, W.C. Knowler, D.J. Pettit, P.H. Bennett, Kidney diseases in diabetes, in: Diabetes in America, 2nd ed., vol. 5, National Institutes of Health Publication No. 95-1468, 1995, pp. 349-400.
3. Fletcher A., Donoghue M. What are optimum blood pressures? Contemp. Int. Med. 8(10):1996;31-44.
4. Peterson J.C., Adler S., Burkart J.M., Greene T., Hebert L.A., Hunsicker L.G., King A., Klahr S., Massry S.G., Seifter J.L. Blood pressure control, proteinuria and the progression of renal disease. The modification of diet in renal disease study. Ann. Intern. Med. 123:1995;754-762.
5. The World Health Organization MONICA Project Ecological analysis of the association between mortality and major risk factors of cardiovascular disease. Int. J. Epidemiol. 23:1994;505.
6. Bruce N.G., Cook D.G., Shaper A.G. Geographical variation in blood pressure in British men and women. J. Clin. Epidemiol. 43:1990;385.
7. McMahon S., Peto R., Cutler J. Blood pressure, stroke and coronary heart disease. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335(1):1990;765.
8. McMahon S. Blood pressure and the risks of cardiovascular disease. Swales J. Textbook of Hypertension. 1994;46 Blackwell, Oxford.
9. Law M.R., Frost C.D., Wald N.J. By how much does dietary salt reduction lower blood pressure? Part I. Analysis of observational data among populations. Br. Med. J. 312:1991;811.
10. National High Blood Pressure Education Program Working Group National high blood pressure education program working group report on hypertension in the elderly. Hypertension. 23:1994;275-285.
11. Coope J., Warrender T.S., McPherson K. The prognostic significance of blood pressure in the elderly. J. Hum. Hypertens. 2:1988;79.
12. Mattila K., Haavisto M., Rajala S. Blood pressure and five-year survival in the very old. Br. Med. J. 296:1988;887.
13. Langer R.D., Ganiats B.G., Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. Br. Med. J. 298:1989;1356.
14. Taylor J.O., Cornoni-Huntley J., Curb J.D. Blood pressure and mortality risk in the elderly. Am. J. Epidemiol. 134:1991;489.
15. Fletcher A.K., Bulpitt C.J. How far should blood pressure be lowered? New Engl. J. Med. 326:1992;251.
16. Cruickshnnk J.M., Thorpe J.M., Zacharias F.J. Benefits and potential harm of lowering blood pressure. Lancet. 1:1987;581.
17. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J. Am. Med. Assoc. 265:1991;3255-3264.
18. Staessen J., Bulpitt C., Clement D. The relationship between mortality and treated blood pressure in elderly patients with hypertension: Report of the European Working Party on high blood pressure in the elderly. Br. Med. J. 298:1989;1552.
19. Coope J., Warrender T.S. Lowering blood pressure. Lancet. 2:1987;518. letter.
20. Sowers J.R., Farrow S.L. Treatment of elderly hypertensive patients with diabetes, renal disease, and coronary heart disease. Am. J. Geriat. Cardiol. 5:1996;57-70.
21. World Health Organization/International Society of Hypertension Memorandum from a World Health Organization/International Society of Hypertension meeting. J. Hypertens. 11:1993;905.
22. The National High Blood Pressure Education Program Working Group National High Blood Pressure Education Progrnm Working Group report on hypertension in diabetes. Hypertension. 23:1994;145-158.
23. Bakris G.L., Copley J.B., Vicknair N., Sadler R., Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy:Results of a six year study. Kidney Int. 50:1996;1641-1650.
24. Sowers J.R., Epstein M. Diabetes mellitus and hypertension: an update. Hypertension. 26(1):1995;869-879.
25. Bakris G.L., Mangrum A., Copley J.B., Vicknair N., Sadler R. Calcium channel or beta blockade on progression of diabetic renal disease in African-Americans. Hypertension. 29:1997;744-750.
26. Group L. Update of the Working Group reports on chronic renal failure and renovascular hypertension. Arch. Intern. Med. 156:1996;1938-1947.
27. Maki D.D., Ma J.Z., Louis T.A., Kasiske B.L. Long-term effects of antibypertensive agents on proteinuria and renal function. Arch. Intern. Med. 155:1995;1073-1080.
28. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. New Engl. J. Med. 329:1993;1456-1462.
29. Ravid M., Lang R., Rachmani R., Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 156:1996;286-289.
30. Estacio R.O., Savage S., Nagel N.J., Schrier R.W. Baseline characteristics of participants in the appropriate blood pressure control in diabetes trials. Control. Clin. Trials. 17:1996;242-257.
31. Mykkanen L., Kuusisto J., Pyorala K., Laakso M., Haffner S.M. Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J. Hypertens. 12:1994;1425-1432.
32. Elliott W.J. Risk factors for the development of diabetes mellitus in unselected patients in a hypertension clinic. Am. J. Hypertens. 5:1992;6. Abstract.
33. Rosansky S.J., Hoover D.R., King L., Gibson J. The association of blood pressure levels and change in renal function in hypertensive and nonhypertensive subjects. Arch. Intern. Med. 150:1990;2073-2076.
34. Lazarus J.M., Bourgoignie J.J., Buckalew V.M., Greene T., Levey A.S., Milas N.C., Paranandi L., Peterson J.C., Porush J.G., Rauch S., Soucie J.M., Stollar for the MDRD group Achievement and safety of a low blood pressure goal in chronic renal disease: the modification of diet in renal disease study group. Hypertension. 29:1997;641-650.
35. Hypertension Detection and Follow-Up Program Five-year findings of the hypertension detection and follow-up program: II. Mortality by race, sex and age group. J. Am. Med. Assoc. 242:1979;2572-2577.
36. Medical Research Council Medical research council trial of treatment of hypertension in older adults: principal results. Br. Med. J. 304:1992;405-412.
37. National High Blood Pressure Education Program Working Group Working group report on hypertension in diabetes. Hypertension. 23:1994;145-158.
38. Bakris G.L., Barnhill B.W., Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 41:1992;912-919.
39. Sowers J.R., Epstein M. Diabetes mellitus and hypertension: an update. Hypertension. 26(1):1995;869-879.
40. WaIker G.W., Neaton J.D., Cutler J.A., Neuwirth R., Cohen J.D. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial: racial and treatment effects. J. Am. Med. Assoc. 268:1992;3085-3091.
41. Tierney W.M., Harris L.E., Copley J.B., Luft F.C. Effect of hypertension and type II diabetes on renal function in an urban population. Am. J. Hypertens. 3:1990;69-75.
42. Rostand S.G., Brown G., Kirk K.A., Rutsky E.A., Dustan H.P. Renal insufficiency in treated essential hypertension. New. Engl. J. Med. 320:1989;684-688.
43. Dillion J.J. The quantitative relationship between treated blood pressure and progression of diabetic renal disease. Am. J. Kidney. Dis. 22:1993;798-802.
44. Toto R., Mitchell H.C., Smith R.D., Lee H.C., McIntire D., Pettinger W.A. 'Strict' blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 48:1995;851-858.
45. Parving H.H., Smidt U.M., Hommel E. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am. J. Kidney Dis. 22:1993;188-195.
46. Perry H.M., Miller J.P., Fornoff J.R. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 25:1995;587-594.
47. Wright J.R., Kusek J., Toto R., Lee J., Agodoa L., Kirk K., Randall O.T., Glassock R. Design and baseline characteristics of participants in the African American Study of Kidney Diseases and Hypertension (AASK) Pilot Study. Control. Clin. Trials. 17:1996;3S-16S.
48. Walker W.G. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am. J. Kidney Dis. 22:1993;164-173.
49. Hebert L.A., Bain R.P., Verne D. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 46:1994;1688-1693.
50. Burt V.L., Cutler J.A., Higgins M., Horan M., Labarthe D., Whelton P., Brown C., Roccella E. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population. Hypertension. 26:1995;60-69.
51. Bakris G.L. Combination therapy for hypertension and renal disease in diabetes. Mogensen C.E. The Kidney and Hypertension in Diabetes Mellitus. 3rd:1997;561-568 Kluwer, Boston.
52. Gaber L., Walton C., Brown S., Bakris G.L. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int. 46:1994;161-169.
53. Munter K., Hergenroder S., Jochims K., Kirchengast M. Individual and combined effects of veraparil on glomerular morphology and function in the stroke prone rat. J. Am. Soc. Nephrol. 7:1996;681-686.
54. Brown S.A., Walton C.L., Crawford P., Bakris G.L. Long-term effects of different anti-hypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 43:1993;1210-1218.
55. Wenzel R.O., Helmchen U., Schoeppe W., Schwietzer G. Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension. 23:1994;114-122.
56. Picken M., Griffin K., Bakris G.L., Bidani A. Effects of a fixed dose combination of either amlodipine, benazapril or their combination on glomerulosclerosis and proteinuria. J. Hypertens. 15:1997;1181-1185.
57. Bakris G.L., Weir M.R., DeQuattro V., Rosendorff C., MacMahon G. Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolapril or calcium antagonist, verapamil, alone or in fixed dose combination in patients with diabetic nephropathy: a randomized multicentered study. Nephrology. 3(Suppl 1):1997;271. Abstract.
58. Lash J.P., Bakris G.L. Effects of ACE inhibitors and calcium antagonists alone or combined on progression of diabetic nephropathy. Nephrol. Dialysis Transpl. 10 (Suppl. 9):1995;56-62.
59. Epstein M., Bakris G.L. Newer approaches to antihypertensive therapy: use of fixed dose combination therapy. Arch. Intern. Med. 156:1996;1969-1978.